28th Nov 2018 13:29
LONDON (Alliance News) - PureTech Health PLC said Wednesday that affiliate Vor Biopharma has been granted a US first-in-class patent covering its technology platform for the treatment of haematological malignancies.
The patent was described as "the first of its kind" in the immuno-oncology field by Vor.
"Vor's technology platform is designed to address the fundamental limitations of traditional targeted therapies with the goal of potentially expanding the reach of targeted immunotherapies beyond B-cell cancers to a broad range of haematological malignancies, including acute myeloid leukaemia," PureTech said.
PureTech Health shares were trading up 1.8% at 179.23 pence each on Wednesday.
Related Shares:
PureTech